Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Endocrine-Related Cancer

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1677/ERC.1.01170PMID 16954435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.

  2005cited by this paper
• Estrogen receptor α and β subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells ☆

  2005influential reference
• Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

  2005cited by this paper
• The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling

  2005cited by this paper
• Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.

  2005cited by this paper
• Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer

  2005cited by this paper
• New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists

  2004cited by this paper
• mTOR signaling to translation.

  2004cited by this paper
• Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

  2004cited by this paper
• mTOR: a protein kinase switching between life and death.

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Mechanisms of hormone resistance in breast cancer

  2004cited by this paper
• Mammalian target of rapamycin (mTOR) inhibitors

  2004cited by this paper
• Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity

  2004cited by this paper
• Rapamycins: Mechanisms of Action and Cellular Resistance

  2003cited by this paper
• Nuclear receptor superfamily: Principles of signaling

  2003cited by this paper
• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation*

  2003influential reference
• The nuclear receptor superfamily

  2003cited by this paper
• Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.

  2003cited by this paper
• Clinical development of mammalian target of rapamycin inhibitors.

  2002cited by this paper
• Human estrogen receptor-α: regulation by synthesis, modification and degradation

  2002cited by this paper
• CCI-779 Wyeth.

  2002cited by this paper
• Human estrogen receptor-alpha: regulation by synthesis, modification and degradation.

  2002cited by this paper
• Highlights from: 38th annual meeting of the American Society of Clinical Oncology.

  2002cited by this paper
• Target of Rapamycin

  2002cited by this paper
• The FKBP12‐rapamycin‐associated protein (FRAP) is a CLIP‐170 kinase

  2002cited by this paper
• Quick guide: target of rapamycin.

  2002cited by this paper
• The TOR Kinases Link Nutrient Sensing to Cell Growth*

  2001cited by this paper
• A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.

  2001cited by this paper
• mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

  2001cited by this paper
• A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review).

  2001cited by this paper
• Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modulators

  2001cited by this paper
• Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.

  2001cited by this paper
• PI 3-kinase, mTOR, protein synthesis and cancer.

  2001cited by this paper
• TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS: A REVIEW

  2001cited by this paper
• A systematic overview of chemotherapy effects in breast cancer.

  2001cited by this paper
• MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells.

  2000cited by this paper
• Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer.

  2000cited by this paper
• Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

  1998cited by this paper
• Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex.

  1997cited by this paper
• A review of endocrine options for the treatment of advanced breast cancer.

  1997cited by this paper
• Use of tamoxifen for breast cancer: twenty-eight years later.

  1995cited by this paper
• A three-dimensional model to analyze drug-drug interactions.

  1990cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper

• A Hypergraph Convolutional Network With Explicit High-Order Interaction Information Extraction for Drug Repositioning

  2025cites this paper
• Emerging mechanisms of therapy resistance in metastatic ER+ breast cancer.

  2025cites this paper
• Progranulin deficiency associates with postmenopausal osteoporosis via increasing ubiquitination of estrogen receptor α

  2024cites this paper
• The SARS-CoV-2 spike protein binds and modulates estrogen receptors

  2022cites this paper
• Single-cell immunoblotting resolves estrogen receptor-α isoforms in breast cancer

  2021cites this paper
• PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects

  2020cites this paper
• Bayesian Inference Identifies Combination Therapeutic Targets in Breast Cancer

  2019cites this paper
• Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells.

  2017cites this paper
• Reappraisal to the study of 4E-BP1 as an mTOR substrate - A normative critique.

  2017cites this paper
• Selective Estrogen Receptor Modulators – an Update (Joint Statement by the German Society for Gynecological Endocrinology and Reproductive Medicine [DGGEF] and the German Professional Association of Gynecologists [BVF])

  2016cites this paper
• Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.

  2014cites this paper
• Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

  2013cites this paper
• Investigation of SSEA-4 binding protein in breast cancer cells.

  2013cites this paper
• mTOR inhibitors in advanced breast cancer: ready for prime time?

  2013cites this paper
• The Relationship Between Estrogen/Progesterone Receptor and Expression of mTOR/pAkt Proteins and the Analysis of Prognosis in Breast Cancer

  2013cites this paper
• Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.

  2013cites this paper
• Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

  2012cites this paper
• Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition

  2012cites this paper
• Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.

  2011cites this paper
• Recent Advances in Anti-Angiogenic Therapy of Cancer

  2011cites this paper
• Enhanced sensitivity to rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75-1 human breast cancer cells.

  2011cites this paper
• Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

  2011cites this paper
• Combination therapy for renal cell carcinoma: review of the clinical evidence

  2011cites this paper
• Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

  2010cites this paper
• Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.

  2009cites this paper
• Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer

  2009cites this paper
• mTOR Mediated Anti-Cancer Drug Discovery.

  2009cites this paper
• Cancer: complexity, causation, and systems biology

  2009cites this paper
• Novel therapeutic strategy for breast cancer: mammalian target of rapamycin inhibition

  2009cites this paper
• Targeting the mTOR signaling network for cancer therapy.

  2009cites this paper
• Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

  2008cites this paper
• Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

  2008cites this paper
• I K B A Kinase Inhibitor IKI-1 Conferred Tumor Necrosis Factor A Sensitivity to Pancreatic Cancer Cells and a Xenograft Tumor Model

  2008cites this paper
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

  2008cites this paper
• mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels

  2008cites this paper
• IkappaBalpha kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor model.

  2008cites this paper
• Chinese Anti鄄 Cancer a Ssociation

  year unknowncites this paper